Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Income: 2017-2024

Historic Net Income for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$43.2 million.

  • Kiniksa Pharmaceuticals International's Net Income rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 142.99%. This contributed to the annual value of -$43.2 million for FY2024, which is 28.48% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Net Income stood at -$43.2 million for FY2024, which was up 28.48% from -$60.4 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Net Income registered a high of $267.4 million during FY2022, and its lowest value of -$167.1 million during FY2020.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Net Income averaged around $54.6 million, with its median value being -$43.2 million (2024).
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Net Income soared by 261.42% in 2022 and then plummeted by 122.58% in 2023.
  • Kiniksa Pharmaceuticals International's Net Income (Yearly) stood at -$167.1 million in 2020, then climbed by 0.88% to -$165.7 million in 2021, then surged by 261.42% to $267.4 million in 2022, then tumbled by 122.58% to -$60.4 million in 2023, then grew by 28.48% to -$43.2 million in 2024.